Cargando…
LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways
Background: Cetuximab is one of the most widely used monoclonal antibodies to treat patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Unfortunately, cetuximab resistance often occurs during targeted therapy. However, the underlying epigenetic mechanisms remain unclear. Our previo...
Autores principales: | Yuan, Heng-heng, Zhang, Xin-chen, Wei, Xiao-li, Zhang, Wen-jie, Du, Xiao-xue, Huang, Peng, Chen, Hao, Bai, Lu, Zhang, Hong-feng, Han, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692674/ https://www.ncbi.nlm.nih.gov/pubmed/34976187 http://dx.doi.org/10.7150/jca.65687 |
Ejemplares similares
-
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer
por: Yang, Ying-nan, et al.
Publicado: (2018) -
lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR-495-3p/MYCBP axis
por: Qian, Jiajie, et al.
Publicado: (2020) -
Circulating lncRNA UCA1 Promotes Malignancy of Colorectal Cancer via the miR-143/MYO6 Axis
por: Luan, Yunpeng, et al.
Publicado: (2019) -
LncRNA—UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p
por: Bian, Zehua, et al.
Publicado: (2016) -
Circulating lncRNA UCA1 and lncRNA PGM5-AS1 act as potential diagnostic biomarkers for early-stage colorectal cancer
por: Wang, Minghui, et al.
Publicado: (2021)